Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:REGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$721.05+2.7%$753.94$476.49▼$821.11$74.24B0.3738,757 shs739,297 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+2.65%+5.05%-5.50%-5.95%+29.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeREGNRegeneron Pharmaceuticals$721.05+2.7%$753.94$476.49▼$821.11$74.24B0.3738,757 shs739,297 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceREGNRegeneron Pharmaceuticals+2.65%+5.05%-5.50%-5.95%+29.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceREGNRegeneron Pharmaceuticals 2.77Moderate Buy$826.5914.64% UpsideCurrent Analyst Ratings BreakdownLatest REGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026REGNRegeneron Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$975.00 ➝ $995.004/30/2026REGNRegeneron Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$779.00 ➝ $762.004/30/2026REGNRegeneron Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$923.00 ➝ $917.004/30/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$801.00 ➝ $796.004/30/2026REGNRegeneron Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$825.00 ➝ $800.004/23/2026REGNRegeneron Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$880.00 ➝ $960.004/23/2026REGNRegeneron Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$800.004/10/2026REGNRegeneron Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$769.00 ➝ $796.004/8/2026REGNRegeneron Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$925.00 ➝ $921.003/31/2026REGNRegeneron Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$818.00 ➝ $801.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookREGNRegeneron Pharmaceuticals$14.92B5.11$43.10 per share16.73$297.23 per share2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateREGNRegeneron Pharmaceuticals$4.50B$41.0417.5717.371.5729.65%13.16%10.17%N/ALatest REGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026REGNRegeneron Pharmaceuticals$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthREGNRegeneron Pharmaceuticals$3.760.52%N/A9.16%N/ALatest REGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026REGNRegeneron Pharmaceuticalsquarterly$0.940.55%5/20/20265/20/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioREGNRegeneron Pharmaceuticals0.063.572.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipREGNRegeneron Pharmaceuticals83.31%Insider OwnershipCompanyInsider OwnershipREGNRegeneron Pharmaceuticals6.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableREGNRegeneron Pharmaceuticals15,410105.72 million98.35 millionOptionableREGN HeadlinesRecent News About These CompaniesTrump’s Affordability Push Stalls Ahead of Midterm Elections1 hour ago | finance.yahoo.comLmcg Investments LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN1 hour ago | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Purchased by K.J. Harrison & Partners Inc2 hours ago | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN2 hours ago | marketbeat.comBluebird Wealth Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNMay 7 at 3:26 AM | marketbeat.comRARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectMay 6 at 3:08 PM | finance.yahoo.comRegeneron Pharmaceuticals, Inc. $REGN Shares Bought by Swedbank ABMay 6 at 7:18 AM | marketbeat.comRegeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoEMay 5 at 1:24 PM | investorshub.advfn.comVarma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGNMay 5 at 8:34 AM | marketbeat.comDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialMay 5 at 8:23 AM | finance.yahoo.comDupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 TrialMay 5 at 7:00 AM | globenewswire.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Horizon Investments LLCMay 5 at 5:52 AM | marketbeat.comArthur Ryan Sells 100 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) StockMay 5 at 5:23 AM | insidertrades.comInsider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 100 Shares of StockMay 4 at 4:50 PM | marketbeat.comHow The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline DevelopmentsMay 4 at 7:55 AM | finance.yahoo.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLCMay 4 at 7:03 AM | marketbeat.comKornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGNMay 4 at 6:28 AM | marketbeat.comBellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGNMay 4 at 3:31 AM | marketbeat.comPKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGNMay 3, 2026 | marketbeat.comStrs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGNMay 3, 2026 | marketbeat.comPFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNMay 3, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREGN Company DescriptionsRegeneron Pharmaceuticals NASDAQ:REGN$721.05 +18.78 (+2.67%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$718.61 -2.44 (-0.34%) As of 09:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
